Alexander Drilon
Alexander Drilon
Verified email at - Homepage
Cited by
Cited by
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ...
New England Journal of Medicine 378 (8), 731-739, 2018
NTRK fusion-positive cancers and TRK inhibitor therapy
E Cocco, M Scaltriti, A Drilon
Nature reviews Clinical oncology 15 (12), 731-747, 2018
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1 …
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 SkippingMET Inhibitors in MET Exon 14 Splice Variant Lung Cancer
PK Paik, A Drilon, PD Fan, H Yu, N Rekhtman, MS Ginsberg, L Borsu, ...
Cancer discovery 5 (8), 842-849, 2015
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
A Drilon, L Wang, A Hasanovic, Y Suehara, D Lipson, P Stephens, J Ross, ...
Cancer discovery 3 (6), 630-635, 2013
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ...
The Lancet Oncology 21 (4), 531-540, 2020
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesMolecular Profiling to Guide …
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ...
New England Journal of Medicine 383 (9), 813-824, 2020
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ...
New England Journal of Medicine 383 (9), 825-835, 2020
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
A Drilon, N Rekhtman, M Arcila, L Wang, A Ni, M Albano, ...
The Lancet Oncology 17 (12), 1653-1660, 2016
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like SubsetsLarge Cell Neuroendocrine …
N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ...
Clinical Cancer Research 22 (14), 3618-3629, 2016
Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions
JF Hechtman, R Benayed, DM Hyman, A Drilon, A Zehir, D Frosina, ...
The American journal of surgical pathology 41 (11), 1547, 2017
Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
JAMA oncology 5 (10), 1411-1420, 2019
Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial
BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ...
Journal of Clinical Oncology 36 (24), 2532, 2018
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
JP Solomon, I Linkov, A Rosado, K Mullaney, EY Rosen, D Frosina, ...
Modern Pathology 33 (1), 38-46, 2020
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid TumorsNext-Generation TRK …
A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ...
Cancer discovery 7 (9), 963-972, 2017
Targeting MET in lung cancer: will expectations finally be MET?
A Drilon, F Cappuzzo, SHI Ou, DR Camidge
Journal of Thoracic Oncology 12 (1), 15-26, 2017
The system can't perform the operation now. Try again later.
Articles 1–20